- Home
- AGEN vs ARTV Comparison
AGEN vs ARTV Comparison
Compare AGEN & ARTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGEN
- ARTV
- Stock Information
- Founded
- AGEN 1994
- ARTV 2019
- Country
- AGEN United States
- ARTV United States
- Employees
- AGEN N/A
- ARTV N/A
- Industry
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- ARTV
- Sector
- AGEN Health Care
- ARTV
- Exchange
- AGEN Nasdaq
- ARTV NYSE
- Market Cap
- AGEN 52.6M
- ARTV 61.9M
- IPO Year
- AGEN 2000
- ARTV 2024
- Fundamental
- Price
- AGEN $2.91
- ARTV $2.08
- Analyst Decision
- AGEN Buy
- ARTV Strong Buy
- Analyst Count
- AGEN 4
- ARTV 7
- Target Price
- AGEN $8.00
- ARTV $20.00
- AVG Volume (30 Days)
- AGEN 830.5K
- ARTV 212.7K
- Earning Date
- AGEN 05-12-2025
- ARTV 05-08-2025
- Dividend Yield
- AGEN N/A
- ARTV N/A
- EPS Growth
- AGEN N/A
- ARTV N/A
- EPS
- AGEN N/A
- ARTV N/A
- Revenue
- AGEN $103,463,000.00
- ARTV N/A
- Revenue This Year
- AGEN $4.03
- ARTV N/A
- Revenue Next Year
- AGEN $5.57
- ARTV N/A
- P/E Ratio
- AGEN N/A
- ARTV N/A
- Revenue Growth
- AGEN N/A
- ARTV N/A
- 52 Week Low
- AGEN $1.38
- ARTV $1.78
- 52 Week High
- AGEN $19.69
- ARTV $17.31
- Technical
- Relative Strength Index (RSI)
- AGEN 59.81
- ARTV N/A
- Support Level
- AGEN $2.87
- ARTV N/A
- Resistance Level
- AGEN $3.16
- ARTV N/A
- Average True Range (ATR)
- AGEN 0.35
- ARTV 0.00
- MACD
- AGEN 0.02
- ARTV 0.00
- Stochastic Oscillator
- AGEN 56.25
- ARTV 0.00
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
About ARTV ARTIVA BIOTHERAPEUTICS INC
Artiva Biotherapeutics Inc is a biopharmaceutical company. The company is engaged in advancing a pipeline of off-the-shelf, allogeneic NK cell therapies for the treatment of hematologic malignancies or solid tumors. The pipeline program of the company includes Artiva-Funded Trials and Collaborator-Funded Trials. The company pipeline includes AlloNK: is an allogeneic, off-the-shelf, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity (ADCC) effect of mAbs to drive B-cell. Others products includes: CAR-NK(AB201),CAR-NK(AB205).